Trump’s MFN policy seeks parity with branded drug pricing in OECD nations

1 month ago 2
Loss of one drug name. Ban on a drug or its shortage. Exclusion from the list of free drugs available under the medical social program.

Andrii Yalanskyi/iStock via Getty Images

The Health and Human Services (HHS) department on Tuesday said under President Donald Trump’s most-favored-nation drug pricing policy, it will require drugmakers to lower prices of branded medicines to the level of those in OECD countries.

The announcement comes a

Recommended For You

Read Entire Article